| Literature DB >> 28714891 |
Stefania Pezzoli1, Annachiara Cagnin2,3, Oliver Bandmann4, Annalena Venneri5.
Abstract
Patients with Lewy body disease (LBD) frequently experience visual hallucinations (VH), well-formed images perceived without the presence of real stimuli. The structural and functional brain mechanisms underlying VH in LBD are still unclear. The present review summarises the current literature on the neural correlates of VH in LBD, namely Parkinson's disease (PD), and dementia with Lewy bodies (DLB). Following a systematic literature search, 56 neuroimaging studies of VH in PD and DLB were critically reviewed and evaluated for quality assessment. The main structural neuroimaging results on VH in LBD revealed grey matter loss in frontal areas in patients with dementia, and parietal and occipito-temporal regions in PD without dementia. Parietal and temporal hypometabolism was also reported in hallucinating PD patients. Disrupted functional connectivity was detected especially in the default mode network and fronto-parietal regions. However, evidence on structural and functional connectivity is still limited and requires further investigation. The current literature is in line with integrative models of VH suggesting a role of attention and perception deficits in the development of VH. However, despite the close relationship between VH and cognitive impairment, its associations with brain structure and function have been explored only by a limited number of studies.Entities:
Keywords: DTI; Lewy body; MRI; PET; Parkinson’s disease; Parkinson’s disease dementia; SPECT; dementia with Lewy bodies; fMRI; visual hallucinations
Year: 2017 PMID: 28714891 PMCID: PMC5532597 DOI: 10.3390/brainsci7070084
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Figure 1Flow chart describing the selection process of the studies included (adapted from Moher et al. [14]). 1 Exclusion criteria: (1) pathologies other than dementia with Lewy bodies (DLB), Parkinson’s disease (PD), or Parkinson’s disease dementia (PDD); (2) neuroimaging analysis not related to visual hallucinations (VH); (3) patients with medication-induced VH; (4) studies not using magnetic resonance imaging (MRI), functional MRI (fMRI), diffusion tensor imaging (DTI), positron emission tomography (PET), and single photon emission computed tomography (SPECT); (5) PET and SPECT studies not investigating glucose metabolism and regional cerebral blood flow; (6) MRI studies using visual rating; (7) magnetic resonance spectroscopic imaging; (8) pharmacological studies; (9) case studies (except for fMRI during VH); (10) review and theoretical articles; (11) non-English articles; and (12) non-peer reviewed articles.
Summary of structural neuroimaging studies of hallucinating patients with LBD. Only main results related to VH are reported.
| Study | Sample | Age 1 | Disease Duration (years) 1 | VH | MMSE 1 | H&Y | Neuroimaging Methods—VH | Main Results: |
|---|---|---|---|---|---|---|---|---|
| Blanc et al. (2016) [ | 28 pro-DLB | 67.5 (9.2) | NA | 60.7% DLB patients | 27.6 (2.1) | NA | Whole brain VBM | Grey matter volume |
| 27 pro-AD | 69.3 (7.8) | 26.9 (1.9) | ||||||
| 33 HC | 72.4 (10.4) | 29.4 (0.9) | ||||||
| Delli Pizzi et al. (2016) [ | 19 DLB VH | 76.37 (4.35) | 2.95 (0.91) | NPI | 18.00 (4.83) | NA | ROI MRI | Grey matter volume |
| 15 AD | 76.47 (7.17) | 3.00 (0.93) | 16.73 (6.31) | |||||
| 19 HC | 76.21 (4.49) | - | 27.58 (0.69) | |||||
| Delli Pizzi et al. (2014) [ | 18 DLB VH | 75.4 (4.0) 2 | 2.9 (0.6) 2 | NPI | 19.1 (2.6) 3,4 | NA | Cortical thickness | Cortical thickness |
| 15 AD | 75.6 (7.6) | 3.1 (0.6) | 18.3 (4.1) | |||||
| 14 HC | 75.5 (5.3) | - | 28.1 (1.6) | |||||
| Delli Pizzi et al. (2014) [ | 15 DLB VH | 76.3 (4.1) 2 | 2.9 (7) 2 | NPI | 17.7 (5.2) 4,5 | NA | DTI ROI | Grey matter MD |
| 15 AD | 76.1 (4.9) | 3.1 (6) | 16.7 (5.4) | |||||
| 13 HC | 76.0 (4.2) | - | 28.3 (1.5) | |||||
| Franciotti et al. (2015) [ | 15 sPD VH | 70 (6) 2 | 11.3 (4.3) 6,7 | NPI and semi-structured interview | 24.3 (2.2) 2 | 3.0 (0.5) 7 | Cortical thickness | Cortical thicknesss |
| 15 sPD NVH | 68 (11) | 12.0 (4.5) 7 | 24.7 (1.8) | 3.0 (0.6) 7 | ||||
| 15 ePD NVH | 66 (9) | 3.3 (1.8) | 26.2 (1.8) | 2.1 (0.4) | ||||
| 15 MSA | 67 (5) | 3.9 (1.8) | 25.2 (1.7) | 3.2 (0.8) | ||||
| 15 HC | 69 (6) | - | 28.7 (0.7) | - | ||||
| Gama et al. (2014) [ | 11 PD VH | 70.6 (9.1) 2 | 7.4 (6.1) 2 | Based on definition of VH | 19.3 (3.7) 9 | From stage I to stage IV | ROI VBM | Grey matter volume |
| 28 PD NVH | 65.7 (7.8) | 6.5 (5.0) | 25.6 (4.3) | |||||
| 10 HC | 68.1 (7.0) | - | 25.6 (4.3) | |||||
| Goldman et al. (2014) [ | 25 PD VH | 74.8 (6.0) 2 | 13.1 (4.6) 2 | MDS-UPDRS | 23.9 (5.4) 2 | 3 (2-5) 2,10 | Whole brain VBM | Grey matter volume |
| 25 PD NVH | 75.4 (6.1) | 10.8 (4.4) | 25.1 (4.4) | 3 (2-5) 10 | ||||
| Ibarretxe-Bilbao et al. (2010) [ | 12 PD VH | 73.3 (5.9) 2 | 12.1 (5.7) 2 | Structured interview; NPI | 26.9 (1.9) 4,9,11 | 3.1 (1.1) 9 | Whole brain VBM | Grey matter loss form baseline to follow-up |
| 14 PD VH | 71.1 (5.7) | 11.9 (4.3) | 29.3 (1.6) | 2.3 (0.5) | ||||
| 12 HC | 70.7 (7.2) | - | 29.5 (2.6) | - | ||||
| Ibarretxe-Bilbao et al. (2008) [ | 16 PD VH | 73.5 (5.1) 2 | 12.9 (5.9) 2 | Structured interview | 26.0 (2.1) 4,9 | 3.2 (1.1) | ROI VBM | Grey matter density |
| 19 PD NVH | 72.5 (5.8) | 10.9 (4.2) | 28.2 (1.7) | 2.5 (0.7) | ||||
| 9 PDD | 69.8 (9.5) | 13.1 (5.4) | 15.7 (5.4) | 3.8 (1.0) 12 | ||||
| 56 HC | 73 (6.7) | - | 28.7 (3.1) | - | ||||
| Iizuka and Kameyama (2016) [ | 24 DLB | 73 (68, 79) 13 | 2.8 (1.8, 3.2) 13 | NPI | 23 (20.5, 24) 13 | NA | ROI MRI | Negative correlation with NPIhall in DLB: MTL atrophy |
| 24 AD | 74 (69, 81) 13 | 2.3 (1.6, 2.6) 13 | 23 (21, 24.5) 13 | |||||
| Janzen et al. (2012) [ | 13 PD VH | 66.0 (6.9) 2 | 11.5 (5.2) | SCOPA-PC | 28.0 (1.7) | 2.5 (0.3) 16 | ROI VBM | Grey matter volume |
| 13 PDD VH | 67.7 (7.1) | 10.9 (5.5) | 21.2 (2.7) 12,14 | 3.5 (1.0) 12,14 | ||||
| 16 PD NVH | 64.3 (8.0) | 3.1 (3.6) | 28.9 (1.6) 15 | 2.1 (0.5) | ||||
| 11 DLB | 62.6 (6.5) | 4.6 (4.5) | 24.5 (1.4) | NA | ||||
| Kantarci et al. (2010) [ | 30 DLB | 71 (55, 85) 10 | NA | VH definition; 64% of DLB | 27 (14, 34) 10,17 | NA | DTI ROI | Mean diffusivity |
| 30 AD | 74 (48, 89) 10 | 24 (5, 33) 10,17 | ||||||
| 60 HC | 73 (54, 86) 10 | 36 (28, 38) 10,17 | ||||||
| Kantarci et al. (2012) [ | 21 DLB | 73 (60, 87) 10 | NA | Freq. of VH: 4 point scale90% of DLB | 22 (6, 29) 10 | NA | ROI MRI | Hippocampal volume |
| 21 AD | 77 (58, 92) 10 | 21 (6, 28) 10 | ||||||
| 42 HC | 74 (59, 87) 10 | 29 (27, 30) 10 | ||||||
| Lee et al. (2016) [ | 10 PD VH | 69.2 (5.2) 2 | 7.2 (3.7) 2 | Semi-structured interview | 27.7 (1.6) 2 | 2.2 (0.5) 2 | DTI ROI | White matter integrity |
| 14 PD NVH | 66.1 (6.1) | 7.3 (3.7) | 28.4 (1.4) | 2.1 (0.5) | ||||
| 15 HC | 68.5 (6.6) | - | NA | - | ||||
| Lee et al. (2017) [ | 10 PD VH | 69.4 (5.3) 2 | 7.2 (3.7) 2 | Based on consensus criteria during clinical follow-up | 27.6 (1.8) | 2.2 (0.3) 12,14,16 | Whole brain VBM | Grey matter volume |
| 21 PD NVH | 66.2 (6.8) | 7.0 (4.2) | 28.2 (1.4) | 1.8 (0.5) | ||||
| 17 PDD VH | 71.1 (5.0) | 6.2 (3.0) | 20.4 (3.7) 12,14 | 2.8 (0.8) | ||||
| 30 HC | 68.6 (6.0) | - | NA | - | ||||
| Meppelink et al. (2011) [ | 11 PD VH | NA 2 | 8.0 (4.7) | NPI | NA 2 | NA | Whole brain VBM | Grey matter volume |
| 13 PD NVH | NA | 7.9 (2.4) | NA | |||||
| 14 HC | NA | - | NA | |||||
| Pagonabarraga et al. (2014) [ | 17 PD mVH | 64.1 (9) 2 | 9.8 (7) 2 | MDS-UPDRS | 87.2 (13) 2, 18 | 1.9 (0.3) 2 | Whole brain VBM | Grey matter volume |
| 29 PD NVH | 66.3 (8) | 7.3 (4) | 90.3 (13) | 1.9 (0.4) | ||||
| 16 HC | 66.8 (8) | - | 91.6 (11) | - | ||||
| Pereira et al. (2013) [ | 6 PD VH | 73.7 (5.4) 2 | 12.9 (5.7) 2 | NPI | 26.1 (2) 4,9 | 3.1 (1) 2 | ROI MRI | Grey matter volume |
| 6 PD NVH | 73.8 (6.8) | 12.8 (6.3) | 27.9 (1.4) | 2.9 (0.9) | ||||
| 6 HC | 73.6 (6.7) | - | 27.9 (2.1) | - | ||||
| Ramirez-Ruiz et al. (2007) [ | 18 PD VH | PD matched with HC | 12.6 (5.6) 2 | NPI and structured questionnaire | 27.0 (2.1) 4,9 | 3.2 (1.0) 9 | Whole brain VBM | Grey matter volume |
| 20 PD NVH | 10.6 (4.3) | 29.1 (1.4) | 2.5 (0.7) | |||||
| 21 HC | - | 29.4 (2.3) | - | |||||
| Sanchez-Castaneda et al. (2010) [ | 6 DLB VH | 70.17 (12.4) 2 | 32.8 (17.7) 19 | NPI and Burnes Questionnaire | 17.5 (5) 2 | 2.6 (0.5) 2 | ROI VBM | Grey matter volume |
| 6 DLB NVH | 70.6 (7.1) | 30 (11.8) 19 | 21.2 (8.1) | 3 (0.7) | ||||
| 8 PDD VH | 75.3 (4.9) | 40.5 (16.8) 19, 20 | 21.5 (3.5) | 2.8 (0.6) | ||||
| 7 PDD NVH | 70.6 (7.1) | 66 (24.8) 19 | 23.5 (4) | 2.6 (1) | ||||
| Shin et al. (2012) [ | 46 PD VH | 71.3 (5.9) 2 | 3.3 (3.0) 2 | NPI | 25.2 (3.0) 2 | NA | Whole brain VBM | Grey matter volume |
| 64 PD NVH | 70.7 (5.7) | 2.8 (3.0) | 25.7 (2.9) | |||||
| Watanabe et al. (2013) [ | 13 PD VH | 66.6 (5.5) 2 | 10.0 (5.2) 2 | UPDRS I | 27.9 (1.9) 2 | 2.9 (0.6) 2 | Whole brain VBM | Grey matter volume |
| 13 PD NVH | 63.6 (10.7) | 10.0 (4.0) | 29.0 (1.5) | 2.4 (0.8) | ||||
| 22 HC | 63.4 (6.1) | - | 29.8 (0.4) | - | ||||
| Yao et al. (2016) [ | 12 PD VH | 70 (64, 72.75) 2, 13 | 9.1 (3.5) 2 | PPRS | 28.5 (24, 29.75) 2,13 | 3.1 (0.7) 2 | ROI MRI | Hippocampal volume and shape: NS |
| 15 PD NVH | 66 (62, 72) 2 | 7.1 (5.1) | 29 (28, 30) 13 | 2.9 (0.7) | ||||
| 14 HC | 63 (62, 68.75) 2 | - | 29 (28, 29.25) 13 | - | ||||
| Yao et al. (2014) [ | 12 PD VH | 67.6 (7.4) 2 | 10.0 (3.5) 2 | PPRS | 27.6 (2.4) 2 | 3.2 (0.7) 2 | Cortical thickness | Cortical thickness |
| 12 PD NVH | 63.4 (7.4) | 8.4 (5.1) | 28.5 (1.7) | 2.8 (0.9) | ||||
| 14 HC | 64.1 (4.0) | - | 29.1 (0.7) | - |
1 Mean (SD); 2 no significant differences between groups; 3 no significant differences with AD; 4 VH ≠ HC; 5 no differences between DLB and AD; 6 no differences between sPD VH and sPD NVH; 7 sPD VH and NVH ≠ ePD; 8 functional neuroimaging is reported in Table A2; 9 VH ≠ NVH; 10 median (range); 11 MMSE: VH 6.5 point decline after 2 years follow-up (higher percentage of loss compared to NVH); 12 PDD ≠ PD NVH; 13 median (interquartile range); 14 PDD ≠ PD VH; 15 PD NVH ≠ DLB; 16 PD VH ≠ PD NVH; 17 Short test of Mental Status; 18 Parkinson’s disease-Cognitive Rating Scale; 19 months; 20 PDD VH ≠ DLB VH, DLB NVH, PDD VH. AD: Alzheimer’s disease; bilat.: bilateral; CAF: Clinician Assessment of Fluctuations; DLB: dementia with Lewy bodies; ed.: education; ePD: early PD; FA: fractional anisotropy ; FAB: Frontal Assessment Battery; FG: fusiform gyrus; freq.: frequency; H&Y: Hoehn and Yahr stage; HC: healthy controls; IFC: inferior frontal cortex; IFG: inferior frontal gyrus; IPL: inferior parietal lobule; ITG: inferior temporal gyrus; LG: lingual gyrus; LGN: lateral geniculate nucleus; LPC: lateral parietal cortex; MD: mean diffusivity; MDS: Movement Disorders Society; MF: middle frontal gyrus; MFC: middle frontal cortex; MMSE: Mini-Mental State Examination; MRI: magnetic resonance imaging; MSA: multiple system atrophy; NA: not available; NPI: Neuropsychiatric Inventory; NPIhall: NPI hallucination score; NS: not significant; NVH: no VH; OFC: orbitofrontal cortex; PCC: posterior cingulate cortex; PD: Parkinson’s disease; PDD: Parkinson’s disease dementia; PFC: prefrontal cortex; PPN: pedunculopontine nucleus; PPRS: Parkinson psychosis rating scale; pro-AD: prodromal AD; pro-DLB: prodromal DLB; project.: projecting; RD: radial diffusivity; ROI: region of interest; SCOPA-PC: Scales for Outcome in Parkinson’s disease Psychiatric Complications; sev.:severity; SFG: superior frontal gyrus; SFS: superior frontal sulcus; SG: supramarginal gyrus; SI: Substantia innominate; sPD: severe PD; SPG: superior parietal gyrus; SPL: superior parietal lobe; STG: superior temporal gyrus; UPDRS: Unified Parkinson’s Disease Rating Scale; VBM: voxel-based morphometry; VH: visual hallucinations.
Summary of functional neuroimaging studies of hallucinating patients with LBD. Only main results related to VH are reported.
| Study | Sample | Age 1 | Disease Duration (years) 1 | VH | MMSE 1 | H&Y | Neuroimaging Methods—VH | Main Results: |
|---|---|---|---|---|---|---|---|---|
| Boecker et al. (2007) [ | 8 PD VH | 72.88 (6.60) 2 | 11.00 (6.46) 2 | NPI | 25.75 (1.67) 2 | 3.31 (0.59) 3 | FDG-PET | Cerebral glucose metabolism |
| 13 PD NVH | 70.56 (6.96) | 8.05 (5.85) | 26.82 (1.54) | 2.68 (1.54) | ||||
| Erskine et al. (2015) [ | 17 DLB | 81.5 (5.5) | NA | NPI | 19.0 (5.1) | NA | Task-based fMRI | fMRI activations |
| 15 AD | 82.5 (9.2) | 20.8 (4.4) | ||||||
| 19 HC | 77.6 (7.1) | 29.0 (1.2) | ||||||
| Firbank et al. (2016) [ | 30 DLB | 76.4 (6.0) | 39.3 (27.9) 7 | NPI | 21.7 (4.2) | NA | FDG-PET | Cerebral glucose metabolism |
| Franciotti et al. (2015) [ | 15 sPD VH | 70 (6) 2 | 11.3 (4.3) 4,5 | NPI and semi-structured interview | 24.3 (2.2) 2 | 3.0 (0.5) 5 | Resting-state fMRI | Functional connectivity of ROIs centred on the DMN |
| 15 sPD NVH | 68 (11) | 12.0 (4.5) 5 | 24.7 (1.8) | 3.0 (0.6) 5 | ||||
| 15 ePD NVH | 66 (9) | 3.3 (1.8) | 26.2 (1.8) | 2.1 (0.4) | ||||
| 15 MSA | 67 (5) | 3.9 (1.8) | 25.2 (1.7) | 3.2 (0.8) | ||||
| 15 HC | 69 (6) | - | 28.7 (0.7) | - | ||||
| Gasca-Salas et al. (2016) [ | 9 PD VH | 70.7 (3.9) 2 | 14.7 (5.4) 2 | UPDRS I | 27 (1.7) 2 | NS differences | FDG-PET | Cerebral glucose metabolism |
| 12 PD NVH | 70.8 (3.4) | 14.3 (6.3) | 25.9 (2.7) | |||||
| 19 HC | 70.1 (3.1) | - | 29.1 (1.2) | |||||
| Goetz et al. (2014) [ | 1 PD VH | 66 | 4 | African tribesmen, chimpanzees, people in civil war uniform, catholic nuns | Intact cognitive function | NA | fMRI during VH | |
| Heitz et al. (2015) [ | 36 DLB VH | 71.7 (10.2) 2 | NA | Assessed by expert neurologists | 21.7 (5.6) 2 | NA | SPECT | Cerebral perfusion |
| 30 DLB NVH | 73.5 (6.9) | 23.3 (4.3) | ||||||
| Holroyd and Wooten (2006) [ | 3 PD VH | 69.7 (8.7) 2 | NA | Based on definition of VH | 31.7 (2.1) 2,8 | NA | Task-based fMRI | fMRI activations |
| 3 PD NVH | 66.0 (2.7) | 34.3 (2.1) 8 | ||||||
| Howard et al. (1997) [ | 1 DLB VH | 74 | 18 7 | Markets, factories, busy roads, docks; no insight | 16 | NA | fMRI during VH | Hallucination-free activations: V1 and V2 bilaterally |
| Iizuka and Kameyama (2016) [ | 24 DLB | 73 (68, 79) 11 | 2.8 (1.8, 3.2) 11 | NPI | 23 (20.5, 24) 11 | NA | FDG-PET | Positive correlation with NPIhall in DLB: CIS ratio |
| 24 AD | 74 (69, 81) 11 | 2.3 (1.6, 2.6) 11 | 23 (21, 24.5) 11 | |||||
| Imamura et al. (1999) [ | 16 DLB VH | 72.5 (4.6) 2 | 23.1 (13.0) 2,7 | NPI | 19.5 (3.9) | NA | FDG-PET | Cerebral metabolic rate of glucose |
| 6 DLB NVH | 72.8 (5.3) | 28.0 (14.4) 7 | 15.0 (3.0) | |||||
| 16 AD | 73.2 (4.6) | 22.2 (13.8) 7 | 19.7 (3.5) | |||||
| Kantarci et al. (2012) [ | 21 DLB | 73 (60, 87) 9 | NA | Freq. of VH: four-point scale | 22 (6, 29) 9 | NA | FDG-PET | Cerebral glucose metabolism |
| 21 AD | 77 (58, 92) 9 | 21 (6, 28) 9 | ||||||
| 42 HC | 74 (59, 87) 9 | 29 (27, 30) 9 | ||||||
| Kataoka et al. (2008) [ | 1 PDD VH | 72 | NA | Well-formed objects, humans, animals; VH developed four years after the onset of parkinsonians symptoms | 27 10 | NA | SPECT during VH | Increased regional cerebral blood flow: L STG, MTG, IFG, and apex of R temporal lobe |
| Lefebvre et al. (2016) [ | 18 PD VH | 63.50 (5.94) 2 | 9.06 (4.11) 2 | NPI | 28.00 (1.24) 2 | 2 (2, 2) 2,11 | Task-based fMRI | Behavioural results |
| 16 PD NVH | 62.69 (4.09) | 8.00 (5.74) | 28.88 (1.20) | 2 (2, 2) 2,11 | ||||
| 17 HC | 62.76 (4.19) | - | 28.47 (1.70) | - | ||||
| Lobotesis et al. (2001) [ | 23 DLB | 79.4 (9) | 60.7 (32) 7 | Detailed psychiatric history | 16.0 (6.1) | NA | SPECT | Regional cerebral blood flow |
| 50 AD | 81.6 (7) | 83.1 (34) | 17.3 (5.5) | |||||
| 20 HC | 78.1 (5) | - | 28.4 (1.5) | |||||
| Matsui et al. (2006) [ | 31 PD VH | 71.1 (8.0) 2 | 10.9 (5.1) 3 | Clinical evaluation and information from patients and caregivers | 25.7 (3.2) 2 | 3.2 (0.4) 2 | SPECT | Brain perfusion |
| 39 PD NVH | 69.0 (7.7) | 6.7 (5.7) | 26.4 (2.8) | 3.0 (0.6) | ||||
| Meppelink et al. (2009) [ | 9 PD VH | 61.2 (8.2) 2 | 8.1 (5.0) 2 | NPI and questionnaire based on VH characteristics in PD | 26.8 (1) 2 | NA | Task-based fMRI | Behavioural results |
| 14 PD NVH | 64.6 (7.8) | 8.7 (4.7) | 27.4 (1.3) | |||||
| 13 HC | 58.5 (7.5) | - | 27.9 (0.9) | |||||
| Miyazawa et al. (2010) [ | 22 DLB | 74.5 (6.9) | NA | Reported by patients and relatives | NA | FDG-PET | Visual hallucinations more frequent in group A | |
| Group A | 74.8 (6.44) 2 | 16.2 (6.95) 2 | ||||||
| Group B | 76.6 (6.29) | 21.0 (5.67) | ||||||
| Nagahama et al. (2010) [ | 100 DLB | 76.7 (6.7) | NA | Semi-structured interview | 21.0 (3.9) | NA | DLB patients: Factor analysis, four factors of psychotic symptoms identified | Regional cerebral blood flow |
| 21 HC | 77.2 (4.8) | - | ||||||
| Nagano-Saito et al. (2004) [ | 8 PD VH | 67.6 (6.2) 2 | 8.6 (5.0) 2 | NA | 28.3 (1.8) 2 | 3.6 (0.9) 2 | FDG-PET | Relative regional cerebral metabolic rate for glucose |
| 11 PD NVH | 66.0 (7.5) | 5.1 (3.8) | 28.5 (1.7) | 3.2 (0.5) | ||||
| 13 HC | 66.2 (4.9) | - | 29.1 (1.0) | - | ||||
| O’Brien et al. (2005) [ | 15 DLB | 73.8 (7) | 2.8 (2.1) | NPIhall decreased over one year | 16.5 (4) | NA | SPECT | Change in perfusion |
| 14 PDD | 71.9 (6) | 2.9 (2.8) | 20.9 (4) | |||||
| Oishi et al. (2005) [ | 24 PD VH | 69.5 (7.2) 2 | 11.1 (5.0) 2 | Clinical evaluation and information from patients and caregivers | 25.1 (3.7) 2 | 3.3 (0.5) 2 | SPECT | Regional cerebral blood flow |
| 41 PD NVH | 68.6 (7.3) | 9.1 (5.0) | 26.5 (3.1) | 3.0 (0.5) | ||||
| Osaki et al. (2005) [ | 20 PD | 60.0 (11.3) | 8.4 (4.2) | Structured clinical assessment | 26.4 (4.1) | NA | SPECT | Regional cerebral blood flow |
| 10 PDD | 61.0 (8.5) | 11.6 (4.1) | 17.4 (6.3) | |||||
| Park et al. (2013) [ | 7 PD VH | 71.0 (4.7) 2 | 5.4 (3.5) 2 | NPI | 26.1 (1.7) 12 | 2 .0 (0.0) 2 | FDG-PET | Cerebral glucose metabolism |
| 8 PD CI VH | 67.8 (6.8) | 6.8 (3.1) | 21.6 (5.1) | 2.2 (0.7) | ||||
| 13 NVH | 66.3 (5.0) | 5.1 (3.1) | 26.9 (1.4) | 1.5 (0.8) | ||||
| Pasquier et al. (2002) [ | 34 DLB | 73.8 (8) | 3.3 (2.5) | NPI | 17.1 (6.7) | NA | SPECT | Cerebral perfusion |
| 28 AD | 76.3 (7.3) | 3.4 (2.7) | 15.8 (6.5) | |||||
| Peraza et al. (2014) [ | 16 DLB | 76.2 (5.7) | NA | NPI | 24.2 (3.75) | NA | Resting-state fMRI | Association with NPIhall: L fronto-parietal, and sensory-motor networks (uncorrected) |
| 17 HC | 77.3 (4.7) | 29.1 (0.83) | ||||||
| Peraza et al. (2015) [ | 18 DLB | 77.2 (6.18) | NA | NPI | 23.6 (3.9) | NA | Resting-state fMRI | No association between integrated network measures and NPIhall |
| 19 AD | 74.7 (8.5) | 22.58 (2.9) | ||||||
| 17 HC | 76.8 (5.7) | 29.1 (0.85) | ||||||
| Perneczky et al. (2008) [ | 14 DLB VH | 69.86 (6.76) 2 | 5.85 (4.88) 2 | NPI | 19.57 (5.27) 2 | NA | FDG-PET | Relative cerebral metabolic rate of glucose |
| 7 DLB NVH | 68.86 (3.02) | 5.71 (2.67) | 23.14 (2.55) | |||||
| 16 HC | 65 (8) | - | 30 (0) | |||||
| Ramirez-Ruiz et al. (2008) [ | 10 PD VH | 73 (1.9) 2 | 11.1 (1.7) 2 | Presence of VHs at least seven times per week, NPI | 25.8 (0.6) 3,13 | 3.1 (0.4) 2 | Task-based fMRI | Behavioural results |
| 10 PD NVH | 72.5 (1.9) | 11 (1.5) | 29.4 (0.4) | 2.5 (0.2) | ||||
| 10 HC | 71.6 (1.6) | - | 29.9 (0.5) | - | ||||
| Shine et al. (2015) [ | 10 PD pBPP | 69.5 (8) 2 | 6.9 (4) 2 | MDS criteria for VH | 26.0 (3) 2,14 | NA | Resting-state fMRI | BPP error score and strength of mental imagery predicted increased connectivity within the VAN and DMN, and decreased connectivity between the DAN and VAN, and the VAN and visual network, and DAN and visual network. |
| 9 PD nBPP | 67.1 (7) | 4.4 (3) | 27.6 (2) 14 | |||||
| 10 HC | 63.5 (8) | - | 28.5 (1) 14 | |||||
| Shine et al. (2015) [ | 21 PD pBPP | 69.3 (6) 2 | 6.0 (3) 2 | UPDRS-II, SCOPA-PC | 27.2 (2) 2,14 | 2.2 (1) 2 | Task-based fMRI | Activity during correctly identified stable items: |
| 14 PD nBPP | 66.3 (5) | 4.7 (4) | 28.6 (2) 14 | 2.1 (1) | ||||
| Stebbins et al. (2004) [ | 12 PD VH | 71.08 (6.39) 2 | 13.92 (4.89) 2 | Self-report, NPI, SAPS | 26.17 (2.25) 2 | 3 (2–4) 2,9 | Task-based fMRI | fMRI activations |
| 12 PD NVH | 73.25 (7.58) | 11.17 (3.90) | 27.96 (2.09) | 3 (2–4) | ||||
| Taylor et al. (2012) [ | 17 DLB | 81.2 (5.6) | 45.4 (32.2) 7,15 | NPI | 18.8 (5.1) | NA | Task-based fMRI | fMRI activations |
| 19 HC | 77.6 (7.1) | - | 29.0 (1.2) | |||||
| Uchiyama et al. (2015) [ | 11 PD VH | 68.3 (1.6) 2 | 6.2 (1.1) 2 | NPI | 27.6 (0.6) 2 | 3.0 (2, 4) 3 | FDG-PET | Glucose cerebral metabolic rate |
| 42 PD NVH | 65.5 (1.0) | 6.3 (0.6) | 28.2 (0.3) | 2.5 (1, 4) | ||||
| 24 HC | 68.0 (1.0) | - | 28.6 (0.3) | - | ||||
| Yao et al. (2016) [ | 12 PD VH | 70 (64, 72.75) 2, 11 | 9.1 (3.5) 2 | PPRS | 28.5 (24, 29.75) 2, 11 | 3.1 (0.7) 2 | Resting-state fMRI | Functional connectivity of the hippocampus |
| 15 PD NVH | 66 (62, 72) 11 | 7.1 (5.1) | 29 (28, 30) 11 | 2.9 (0.7) | ||||
| 14 HC | 63 (62, 68.75) 11 | - | 29 (28, 29.25) 11 | - | ||||
| Yao et al. (2015) [ | 12 PD VH | 67.6 (7.4) 2 | 10.0 (3.5) 2 | PPRS | 27.6 (2.4) 2 | 3.2 (0.7) 2 | Resting-state fMRI | ALFF |
| 12 PD NVH | 63.4 (7.4) | 8.4 (5.1) | 28.5 (1.7) | 2.8 (0.9) | ||||
| 14 HC | 64.1 (4.0) | - | 29.1 (0.7) | - | ||||
| Yao et al. (2014) [ | 12 PD VH | 67.6 (7.4) 2 | 10.0 (3.5) 2 | PPRS | 27.6 (2.4) 2 | 3.2 (0.7) 2 | Resting-state fMRI | Functional connectivity in the DMN |
| 12 PD NVH | 63.4 (7.4) | 8.4 (5.1) | 28.5 (1.7) | 2.8 (0.9) | ||||
| 14 HC | 64.1 (4.0) | - | 29.1 (0.7) | - |
1 Mean (SD); 2 no significant differences between groups; 3 VH ≠ NVH; 4 no differences between sPD VH and sPD NVH; 5 sPD VH and NVH ≠ ePD; 6 structural neuroimaging is reported in Table A1; 7 months; 8 Telephone Interview for Cognitive Status; 9 median (range); 10 one year before the development of VH, while three years after was 23; 11 median (interquartile range); 12 differences between groups; 13 VH ≠ HC; 14 MoCA; 15 duration of dementia. ACC: anterior cingulate cortex; AD: Alzheimer’s disease; ALFF: amplitude of low-frequency fluctuation; ASL: arterial spin labelling; BOLD: blood-oxygenation level-dependent; BPP: bistable percept paradigm; CAMCOG: Cambridge cognitive examination; ChEI: cholinesterase inhibitor; CI: cognitive impairment; CIS: cingulate island sign; DAN: dorsal attention network; DLB: dementia with Lewy bodies; DMN: default mode network; DTI: diffusion tensor imaging; ed.: education; ePD: early PD; fALFF: fractional amplitude of low-frequency fluctuation; FC: functional connectivity; FDG: [18F]-Fluorodeoxyglucose; freq.: frequency; FG: fusiform gyrus; fMRI: functional MRI; H&Y: Hoehn and Yahr stage; HDRS: Hamilton depression rating scale; hypermetab.: hypermetabolism; ICA: independent component analysis; IFG: inferior frontal gyrus; IOG: inferior occipital gyrus; IPL: inferior parietal lobule; ITG: inferior temporal gyrus; L: left; LG: lingual gyrus; LGN: lateral geniculate nucleus; LPC: lateral parietal cortex sPD; MFG: middle frontal gyrus; MMSE: Mini-Mental State Examination; MoCA: Montreal Cognitive Assessment; MOG: middle occipital gyrus; MRI: magnetic resonance imaging; MSA: multiple system atrophy; MTG: middle temporal gyrus; MTL: medial temporal lobe; NA: not available; nBPP; NPI: Neuropsychiatric Inventory; NPIhall: NPI hallucination score; NS: not significant; NVH: no VH; pBPP: positive bistable percept paradigm; PCC: posterior cingulate cortex; PD: Parkinson’s disease; PDD: Parkinson’s disease dementia; PET: positron emission tomography; PFC: prefrontal cortex; R: right; ROI: region of interest; sev.: severity; SFS: superior frontal sulcus; SG: supramarginal gyrus; STG: superior temporal gyrus; STL: superior temporal lobe; SUVR: standardized uptake value ratio; SVC: small volume correction; TMT: trial making test; UPDRS: Unified Parkinson’s Disease Rating Scale; VAN: ventral attention network; VH: visual hallucinations; VIS: visual network.
Summary of the most consistent findings associated with VHs in LBD.
| Brain Regions | GM Volume | Functional Connectivity | Task-Related BOLD Activation | Glucose Metabolism | Brain Perfusion |
|---|---|---|---|---|---|
| Frontal | ↓ | ↑ | ↑↓ | ↓↑ | |
| Parietal | ↓ | ↑ | ↓↑ | ||
| Temporal | ↓↑ | ||||
| Occipito- temporal | ↓ | ↓↑ | ↓ | ||
| Occipital | ↓↑ | ↓ |
BOLD: blood-oxygenation level-dependent; GM: grey matter; LBD: Lewy body disease; VH: visual hallucinations; ↓: decrease; ↑: increase.